0
Signin
countryflagUS

18889881171

AAPL 258.8189 0.2397% MSFT 439.14 -0.0432% NVDA 140.185 -0.025% GOOGL 196.0128 -0.0496% GOOG 197.54 -0.0152% AMZN 227.87 -0.5152% META 603.74 -0.6598% AVGO 245.6915 2.5081% TSLA 452.9125 -2.0264% TSM 204.19 -1.0372% LLY 797.2122 0.1938% V 320.96 0.0967% JPM 242.37 0.0248% UNH 509.62 0.6955% NVO 87.85 0.5494% WMT 92.38 -0.3237% LVMUY 132.91 0.4459% XOM 106.31 -0.0846% LVMHF 664.0 0.9119% MA 536.2159 0.0944%

Premier Biomedical Inc

Healthcare US BIEI

0.0007USD
-(-%)

Last update at 2024-12-24T14:30:00Z

Day Range

0.00070.0007
LowHigh

52 Week Range

0.00060.0021
LowHigh

Fundamentals

  • Previous Close 0.0007
  • Market Cap0.88M
  • Volume0
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-0.32390M
  • Revenue TTM0.01M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00142M
  • Diluted EPS TTM-0.01

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2019-12-31 2018-12-31 2017-12-31 2016-12-31 2015-12-31
Type yearly yearly yearly yearly yearly
Date 2019-12-31 2018-12-31 2017-12-31 2016-12-31 2015-12-31
Income before tax -0.37447M -0.39889M -3.76356M -1.76822M -2.58217M
Minority interest - 0.00000M 0.00000M 0.00000M 0.00000M
Net income -0.37447M -0.39889M -3.76356M -1.76822M -2.58217M
Selling general administrative 0.33M 0.62M 1.12M 0.52M 2.15M
Selling and marketing expenses - - - - -
Gross profit 0.00142M -0.07393M 0.01M 0.00000M 0.00000M
Reconciled depreciation 0.00283M 0.00230M 0.00232M - -
Ebit -0.32673M -0.71834M -1.63703M -0.63789M -2.38328M
Ebitda -0.32390M -0.71604M -1.63471M -0.63581M -2.38182M
Depreciation and amortization 0.00283M 0.00230M 0.00232M 0.00208M 0.00146M
Non operating income net other - 0.00000M 0.00000M 0.00000M 0.00000M
Operating income -0.32673M -0.69284M -1.28984M -0.63789M -2.38328M
Other operating expenses 0.34M 0.76M 1.33M 0.64M 2.38M
Interest expense 0.39M 0.39M 0.01M 0.82M 0.20M
Tax provision - - - - -
Interest income - - - - -
Net interest income -0.39255M -0.38979M -0.35150M -0.81742M -
Extraordinary items - 0.00000M 0.00000M 0.00000M 0.00000M
Non recurring - 0.00000M 0.00000M 0.00000M 0.00000M
Other items - 0.00000M 0.00000M 0.00000M 0.00000M
Income tax expense 0.39M 0.39M 0.00431M 0.82M 0.00000M
Total revenue 0.01M 0.04M 0.04M 0.00000M 0.00000M
Total operating expenses 0.33M 0.64M 1.30M 0.64M 2.38M
Cost of revenue 0.01M 0.11M 0.03M 0.00000M 0.00000M
Total other income expense net 0.34M 0.71M -2.12222M -0.31291M -0.19889M
Discontinued operations - 0.00000M 0.00000M 0.00000M 0.00000M
Net income from continuing ops -0.37447M -0.39889M -3.76356M -1.76822M -2.60141M
Net income applicable to common shares -0.37447M -0.39889M -3.76356M -1.76822M -2.60141M
Preferred stock and other adjustments - 0.00000M 0.00000M 0.00000M 0.00000M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 0.00735M 0.00313M 0.00313M 0.00460M 0.10M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets - - - - 0.00713M
Total liab 2.49M 2.28M 2.25M 2.22M 1.93M
Total stockholder equity -2.48207M -2.27990M -2.24893M -2.21516M -1.83282M
Deferred long term liab - - - - -
Other current liab 1.92M 1.85M 1.60M 1.58M 1.55M
Common stock 0.01M 0.01000M 0.01000M 0.01000M 0.00262M
Capital stock - - - - 0.00475M
Retained earnings -17.85505M -17.65287M -17.60361M -17.56484M -17.10217M
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash 0.00421M - - - 0.07M
Cash and equivalents - - - - -
Total current liabilities 2.49M 2.28M 2.25M 2.22M 1.93M
Current deferred revenue - - - - 0.06M
Net debt 0.56M 0.44M 0.44M 0.42M 0.09M
Short term debt 0.57M 0.44M 0.44M 0.42M 0.16M
Short long term debt - - - - 0.16M
Short long term debt total 0.57M 0.44M 0.44M 0.42M 0.16M
Other stockholder equity 15.37M 15.37M 15.35M 15.35M 15.26M
Property plant equipment - - - - 0.00722M
Total current assets 0.00421M - - - 0.09M
Long term investments - - - - -
Net tangible assets - - - - -1.83495M
Short term investments - - - - -
Net receivables - - - - 0.00227M
Long term debt - - - - -
Inventory - - - - 0.01M
Accounts payable - - 0.22M 0.22M 0.22M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.01099M -0.00901M -0.01000M -0.01000M -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.00000M - - - 0.00722M
Deferred long term asset charges - - - - -
Non current assets total 0.00313M 0.00313M 0.00313M 0.00460M 0.00722M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2019-12-31 2018-12-31 2017-12-31 2016-12-31 2015-12-31
Type yearly yearly yearly yearly yearly
Date 2019-12-31 2018-12-31 2017-12-31 2016-12-31 2015-12-31
Investments -0.00485M -0.00203M -0.00269M -0.00354M 0.00000M
Change to liabilities -0.06874M -0.09785M 0.11M 0.04M 0.07M
Total cashflows from investing activities -0.00485M -0.00203M -0.00269M -0.00354M -0.00354M
Net borrowings 0.33M 0.30M 0.27M 0.33M 0.40M
Total cash from financing activities 0.33M 0.45M 0.57M 0.47M 0.40M
Change to operating activities 0.11M 0.01M -0.01843M 0.41M 0.02M
Net income -0.37447M -0.39889M -3.76356M -1.76822M -2.58217M
Change in cash -0.01563M 0.00312M 0.06M -0.01298M -0.06718M
Begin period cash flow 0.09M 0.08M 0.02M 0.04M 0.10M
End period cash flow 0.07M 0.09M 0.08M 0.02M 0.04M
Total cash from operating activities -0.34418M -0.44488M -0.50943M -0.48362M -0.46222M
Issuance of capital stock 0.00000M 0.15M - - -
Depreciation 0.00283M 0.00230M 0.00232M 0.00208M 0.00146M
Other cashflows from investing activities - 0.00000M 0.00000M 0.00000M 0.00000M
Dividends paid - 0.00000M 0.00000M 0.00000M 0.00000M
Change to inventory 0.01M -0.02887M -0.08476M -0.08476M -0.08476M
Change to account receivables 0.00083M -0.00278M -0.00031M -0.00031M -0.00031M
Sale purchase of stock - 0.00000M 0.00001M 0.00000M 0.00000M
Other cashflows from financing activities -0.00485M 0.30M 0.30M 0.56M 0.00000M
Change to netincome -0.34508M -0.29915M 2.90M 0.08M 1.87M
Capital expenditures 0.00485M 0.00203M 0.00269M 0.00354M 0.00354M
Change receivables - 0.00000M 0.00000M 0.00000M 0.00000M
Cash flows other operating - 0.00000M 0.00000M 0.00000M 0.00000M
Exchange rate changes - 0.00000M 0.00000M 0.00000M 0.00000M
Cash and cash equivalents changes - 0.00000M 0.00000M 0.00000M 0.00000M
Change in working capital 0.05M -0.11580M 0.01M 0.45M 0.09M
Stock based compensation 0.00000M 0.30M 0.78M 0.11M 1.85M
Other non cash items -0.02467M -0.22944M 2.46M 0.72M 0.18M
Free cash flow -0.34903M -0.44691M -0.51213M -0.48716M -0.46222M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BIEI
Premier Biomedical Inc		 - -% 0.0007 - - 61.56 - 112.03 76.52
ZTS
Zoetis Inc		 0.35 0.22% 165.06 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 -0.04 0.14% 28.78 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 - -% 141.27 21.73 14.95 3.16 2.15 3.56 12.82
TAK
Takeda Pharmaceutical Co Ltd ADR		 -0.02 0.15% 13.15 32.67 11.53 0.01 0.87 0.02 0.07

Reports Covered

Stock Research & News

View All

Profile

Premier Biomedical, Inc., a research-based company, discovers and develops medical products for the treatment of PTSD, cancer, and various other diseases. It offers pain management products comprising pain relief patch of hemp oil extracts; water-based and oil-based roll-on applicators; oil-based pump spray applicators; and ointments through its Website painreliefmeds.com and various distributors. It is also developing hemp oil products, including anti-pain patch, roll-on topical products, sprays, ointments, tincture drop product, a hemp oil capsule, and pet product; sequential-dialysis technique for cancer, Alzheimer's disease, ALS, blood sepsis, leukemia, and other life-threatening cancers; and Feldetrex drug candidate for the treatment of multiple sclerosis, fibromyalgia, neuropathic pain, and traumatic brain injuries. Premier Biomedical, Inc. was founded in 2010 and is headquartered in Jackson Center, Pennsylvania.

Premier Biomedical Inc

PO Box 25, Jackson Center, PA, United States, 16133

Key Executives

Name Title Year Born
Mr. David Caplan Pres, Chairman of Directors, Sec. & Treasurer NA
Mr. Carl Eller Marketing & Planning Vice-Pres NA
Mr. David Caplan President, Chairman of the Board of Directors, Secretary & Treasurer NA
Mr. Gustavo Carreño Chief Technology Officer NA
Mr. Carl Eller Marketing & Planning Vice-President NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.